Articles

Podcasts

Videos

GASTROINTESTINAL INFECTIONS

What are the efforts being made with antibiotic stewardship and treatments, and what areas in clinical care do medical professionals want to see improvements.  

Where Are We With Clostridioides Difficile?

The company’s RBX2660, administered as a single dose, demonstrated superiority  over standard of care for reducing Clostridioides difficile infection (CDI) recurrence.

Ferring’s Microbiota Therapy for C Diff Shows Promise 

This event will be a free, virtual event in July with expert speakers and survivors.

Clostridioides Difficile Infection Symposium for Patients, Families, Caregivers

Investigators apply guidelines into practical management strategies.

Clostridioides difficile Infection: Diagnosis, Testing, Screening, and Treatment

The organizations set out 3 recommendations for initial and recurrent C diff treatment.

IDSA, SHEA Announce New Clostridioides Difficile Clinical Guidelines

During the COVID-19 surge last year, the federal government stopped the required reporting on healthcare-associated infections (HAI) thus leaving an absence of data and important information on HAI. One study examined the effect the initial pandemic surge had on Clostridioides Difficile infection (CDI) in one hospital. 

How Did COVID-19 Affect Clostridioides Difficile Testing and Incidence Rates?

An assessment of the frontline agents show similarities infection cure and recurrence rates at 30 days.

Stem Cell Patients with C Difficile Benefit from Vancomycin, Fidaxomicin

Ferring Pharmaceuticals and Rebiotix reported results from a trial on their therapy, RBX2660, which shows promise as a Clostridioides difficile infection (CDI) treatment.

Investigational Clostridioides Difficile Therapy Demonstrates Superiority Over Placebo

A study looked at hospital admissions of Medicare patients and saw a large percentage of recurrent Clostridioides difficile infections (rCDI) as the primary diagnosis.

The Burden of Clostridioides Difficile

An effort to increase stewardship showed that 5-day and 10-day prescription stop dates for antibiotics did little to influence actual therapy length and outcomes.

C. DIFFICILE